According to relative SPRY4-IT1 expression in tumor tissues, the 121 NSCLC patients were classified into two groups: the high SPRY4-IT1 group (n=60, fold change ≤ median) and the low SPRY4-IT1 group (n=61, fold change ≥ median) (Figure 1b). The gene discussed is SPRY4; the disease is non-small cell lung carcinoma.